(Q43923967)

28 November 2017

title

Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction (English)

1 reference

28 November 2017

1 reference

1 reference

1 reference

2

1 reference

28 November 2017

Sanjay M Sisodiya

1

1 reference

28 November 2017

Philip N Patsalos

series ordinal

3

1 reference

28 November 2017

publication date

1 February 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

48

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

217-219

1 reference

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

Long-term continuation of levetiracetam in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

New antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900309-6

7 January 2021

10.1016/S0920-1211(01)00309-6

Identifiers

DOI

1 reference

28 November 2017

1 reference